Sparsentan: a drug that treats proteinuria and how effective it is

As a new drug for treating urinary protein, Sparsentan has shown significant efficacy in the field of kidney disease treatment, especially in the control of proteinuria in patients with IgA nephropathy (immunoglobulin A nephropathy).

Sparsentan is an endothelin-angiotensin dual blocker that can simultaneously block endothelinA type (ETA) receptors and angiotensinII Type 1 (AT1) receptor. This dual blocking mechanism gives sparsentane a unique advantage in reducing proteinuria. By inhibiting these two key pathways that lead to kidney damage, sparsentin can effectively protect glomerular podocytes and prevent damage to the glomerular filtration barrier, thereby reducing protein leakage from urine.

The efficacy of sparsentane has been fully verified in multiple clinical trials. Take the PROTECT study as an example. This is an international, randomized, double-blind, active drug-controlled study involving 134 clinical practice sites in 18 countries around the world. The results of the study showed that compared with the control drug irbesartan, sparsentan can significantly reduce proteinuria levels in patients with IgA nephropathy. Specifically, the geometric least squares mean percent change from baseline in the urinary protein-to-creatinine ratio at week 36 was -49.8% in the sparsentan group and only -15.1% in the irbesartan group. This result suggests that sparsentan is far more effective than irbesartan in reducing proteinuria.

Although sparsentane is excellent at reducing proteinuria, patients still need to be aware of possible side effects during use. According to information from clinical trials and drug inserts, common side effects of sparsentan include hypotension (including orthostatic hypotension), peripheral edema, dizziness, anemia, hyperkalemia, etc. In addition, some patients may also experience liver function abnormalities such as elevated transaminases. Therefore, patients should undergo detailed liver function tests before using sparsentane and monitor relevant indicators regularly during treatment. At the same time, patients should also follow the doctor's guidance, use medication rationally, and avoid adjusting the dosage or stopping medication on their own.